Alkem Laboratories Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Vikas Gupta

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	1.1yrs
Promedio de permanencia en la Junta Directiva	7.9yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Vikas Gupta

less than a year

Permanencia

Dr. Vikas Gupta is Chief Executive Officer of Alkem Laboratories Limited from September 22, 2023. He has experience in Pharmaceutical Sector and brings with him deep experience across therapeutic areas inc...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Basudeo Singh	Executive Chairman	50.7yrs	₹192.50m	13.31% ₹ 74.0b
Sarvesh Singh	VP of Sales & Marketing and Executive Director	no data	₹43.30m	0.067% ₹ 371.1m
Sandeep Singh	MD & Executive Director	less than a year	₹82.70m	0.0065% ₹ 36.3m
Mritunjay Singh	Executive Director	no data	₹95.90m	8.88% ₹ 49.4b
Srinivas Singh	Executive Director	1.6yrs	₹98.91m	0.086% ₹ 477.6m
Madhurima Singh	Executive Director	no data	₹94.90m	7.96% ₹ 44.3b
Vikas Gupta	Chief Executive Officer	less than a year	sin datos	sin datos
Nitin Agrawal	Chief Financial Officer	less than a year	sin datos	sin datos
Satish Singh	Head of Operations	no data	sin datos	0.060% ₹ 334.5m
Amit Khandelia	Investor Relations Officer	2.3yrs	sin datos	sin datos
Manish Narang	President of Legal	7.8yrs	₹14.50m	sin datos
Satyavan Manikani	Assistant Vice President of Strategy and Business Development	no data	sin datos	sin datos

1.1yrs

Permanencia media

55yo

Promedio de edad

Equipo directivo experimentado: 539523El equipo directivo de la empresa no se considera experimentado ( 0.9 años de permanencia media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Basudeo Singh	Executive Chairman	50.7yrs	₹192.50m	13.31% ₹ 74.0b
Sarvesh Singh	VP of Sales & Marketing and Executive Director	4.4yrs	₹43.30m	0.067% ₹ 371.1m
Sandeep Singh	MD & Executive Director	10.7yrs	₹82.70m	0.0065% ₹ 36.3m
Mritunjay Singh	Executive Director	15.4yrs	₹95.90m	8.88% ₹ 49.4b
Srinivas Singh	Executive Director	1.6yrs	₹98.91m	0.086% ₹ 477.6m
Madhurima Singh	Executive Director	2.3yrs	₹94.90m	7.96% ₹ 44.3b
Arun Purwar	Independent Director	9.1yrs	₹3.10m	sin datos
Sudha Ravi	Independent Director	8.8yrs	₹2.90m	sin datos
Sangeeta Singh	Independent Director	8.8yrs	₹3.20m	sin datos
Dheeraj Sharma	Independent Director	6.9yrs	₹3.10m	sin datos
Narendra Aneja	Additional Independent Director	4.1yrs	₹3.00m	sin datos
Sujjain Talwar	Independent Director	1.7yrs	₹1.90m	sin datos

7.9yrs

Permanencia media

59.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 539523 se considera experimentada (7.7 años de antigüedad promedio).

Alkem Laboratories Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Alkem Laboratories Limited Announces CFO Changes

Alkem Laboratories Limited Appoints Ashish Sehgal to Hold Senior Management Position in the Company Effective 15 December 2023

Alkem Laboratories Limited Appoints Kaustav Banerjee to Hold Senior Management Position

Alkem Laboratories Appoints Sanchit Bansal to Senior Management Position

Alkem Laboratories Limited Appoints Madhurima Singh, Executive Director

Alkem Laboratories Limited Appoints Vikas Gupta as the Chief Executive Officer, Effective 22nd September, 2023

Recent updates

Price target increased by 15% to ₹4,936

Price target increased by 9.5% to ₹4,523

Third quarter 2024 earnings released: EPS: ₹49.76 (vs ₹38.03 in 3Q 2023)

Alkem Laboratories Limited Approves Interim Dividend for Financial Year 2023-24 , Payable on 1 March, 2024

Alkem Laboratories Limited Announces CFO Changes

Alkem Laboratories Limited Appoints Ashish Sehgal to Hold Senior Management Position in the Company Effective 15 December 2023

Alkem Laboratories Limited Submits Clinical Trial Application for First Patient Study with Bsg005 in Invasive Fungal Infections in India as A Rescue Therapy

Alkem Laboratories Limited Appoints Kaustav Banerjee to Hold Senior Management Position

Alkem Laboratories Appoints Sanchit Bansal to Senior Management Position

Alkem Laboratories Limited Appoints Madhurima Singh, Executive Director

Price target increased by 7.5% to ₹3,956

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Alkem Laboratories Limited to Report Q2, 2024 Results on Nov 07, 2023

Alkem Laboratories Limited Appoints Vikas Gupta as the Chief Executive Officer, Effective 22nd September, 2023

Alkem Laboratories Limited Appoints Vikas Gupta as the Chief Executive Officer, Effective 22nd September, 2023

Price target increased by 7.5% to ₹3,612

Upcoming dividend of ₹10.00 per share at 0.6% yield

Alkem Laboratories Limited to Report Q1, 2024 Results on Aug 10, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Alkem Laboratories Limited Recommends Final Dividend for Financial Year Ended March 31, 2023, Payable on and from August 30, 2023

Alkem Laboratories Limited, Annual General Meeting, Aug 25, 2023

Alkem Laboratories Limited to Report Q4, 2023 Results on May 19, 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alkem Laboratories Limited Declares Special Dividend for the Financial Year 2022-2023, Payable Be on and from 01 March, 2023

Alkem Laboratories Limited Declares Interim Dividend for the Financial Year 2022-2023, Payable on 1 March 2023

Alkem Laboratories Limited to Report Q3, 2023 Results on Feb 10, 2023

Eight Roads Ventures India Healthcare IV, L.P entered into a Shareholders’ Agreement to acquire a minority stake in Enzene Biosciences Ltd from Alkem Laboratories Limited (BSE:539523) for INR 1614.83 million.

Consensus forecasts updated

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

High number of new directors

U.S. Food and Drug Administration Conducts Pre-Approval Inspection At Alkem Laboratories Limited Manufacturing Facility Located At St. Louis, Usa

Alkem Laboratories Limited Appoints Srinivas Singh as (Executive) Additional Director and Whole Time Director

Alkem Laboratories Limited Announces Retirement of Balmiki Prasad Singh as Executive Director

Consensus EPS estimates fall by 11%

Price target decreased to ₹3,357

Alkem Laboratories Limited Appoints Sujjain Talwar as an Additional Director, Designated as an Independent Director on the Board of Directors

Upcoming dividend of ₹4.00 per share

Alkem Laboratories Limited to Report Q1, 2023 Results on Aug 05, 2022

Less than half of directors are independent

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Alkem Laboratories Limited Announces Resignation of Ranjal Laxmana Shenoy as Non- Executive Independent Director

Price target decreased to ₹3,624

Alkem Laboratories Limited Proposes Final Dividend for Financial Year Ended 31 March, 2022

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider recently sold ₹90m worth of stock

Executive Director recently bought ₹16m worth of stock

The Pharma Network LLC acquired 100% shares of S&b Pharma, Inc from Alkem Laboratories Limited (BSE:539523).

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Insider recently sold ₹17m worth of stock

Insider recently sold ₹18m worth of stock

Second quarter 2022 earnings released: EPS ₹45.52 (vs ₹39.48 in 2Q 2021)

Insider recently sold ₹19m worth of stock

Price target increased to ₹3,793

Alkem Laboratories Limited Launches Ibuprofen and Famotidine Tablets in the United States

Upcoming dividend of ₹5.00 per share

Full year 2021 earnings released: EPS ₹133 (vs ₹94.26 in FY 2020)

Insider recently sold ₹31m worth of stock

Alkem Launches Perampanel Tablets in India Under the Brand Name "Perampil" for Treatment of Epilepsy

Alkem Laboratories Limited Recommends Final Dividend for Financial Year Ended March 31, 2021, Payable on and from September 1, 2021

Insider recently sold ₹26m worth of stock

ALKEM Launches Brivaracetam in India Under the Brand Name Brivasure for Treatment of Epilepsy

Third quarter 2021 earnings released: EPS ₹37.72 (vs ₹31.95 in 3Q 2020)

Earnings beat expectations, revenue disappoints

Alkem Laboratories Limited to Report Q3, 2021 Results on Feb 05, 2021

New 90-day high: ₹2,968